Online inquiry

IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5394MR)

This product GTTS-WQ5394MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD2 gene. The antibody can be applied in Psoriasis, severe chronic plaque research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001328609.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 914
UniProt ID P06729
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5394MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7989MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GX-H9
GTTS-WQ13949MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-2810
GTTS-WQ7775MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GS-5745
GTTS-WQ2946MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ANB-011
GTTS-WQ8298MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HM-12525A
GTTS-WQ8198MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA hLIV22
GTTS-WQ1365MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABT-874
GTTS-WQ6070MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CNTO 888
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW